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Objective: Attention deficit hyperactivity disorder (ADHD) is a common and highly heritable 
neurodevelopmental disorder with a complex pathophysiology. Intracranial volume (ICV) and 
volumes of the nucleus accumbens, amygdala, caudate nucleus, hippocampus, and putamen are 
smaller in people with ADHD compared with healthy individuals. The authors investigated the 
overlap between common genetic variation associated with ADHD risk and these brain volume 
measures to identify underlying biological processes contributing to the disorder.
Methods: The authors combined genome-wide association results from the largest available 
studies of ADHD (N=55,374) and brain volumes (N=11,221–24,704), using a set of 
complementary methods to investigate overlap at the level of global common variant genetic 
architecture and at the single variant level.
Results: Analyses revealed a significant negative genetic correlation between ADHD and ICV 
(rg= −20.22). Meta-analysis of single variants revealed two significant loci of interest associated 
with both ADHD risk and ICV; four additional loci were identified for ADHD and volumes of the 
amygdala, caudate nucleus, and putamen. Exploratory gene-based and gene-set analyses in the 
ADHD-ICV meta-analytic data showed association with variation in neurite outgrowth-related 
genes.
Conclusions: This is the first genome-wide study to show significant genetic overlap between 
brain volume measures and ADHD, both on the global and the single variant level. Variants linked 
to smaller ICV were associated with increased ADHD risk. These findings can help us develop 
new hypotheses about biological mechanisms by which brain structure alterations may be involved 
in ADHD disease etiology.
Attention deficit hyperactivity disorder (ADHD) is a common, highly heritable (1, 2) 
neurodevelopmental disorder with a complex and heterogeneous pathophysiology. Pathways 
toward disease are hypothesized to be mediated by alterations in diverse brain networks (1). 
A recent neuroimaging mega-analysis (3) reported subtle but consistent differences in 
volumes of subcortical brain regions and intracranial volume (ICV) in ADHD, across 
diverse cohorts worldwide: compared with healthy control subjects, patients with ADHD 
showed decreased ICV and volumes of the nucleus accumbens, amygdala, caudate nucleus, 
hippocampus, and putamen. How such alterations contribute to the disease phenotype is still 
poorly understood. However, brain volume alterations are also present, on average, in 
unaffected relatives of patients with ADHD (4, 5), and both ADHD and brain volumes have 
high heritability (60%–70% [2, 6] and 70%–90% [7], respectively). This suggests that 
genetic variants underlying ADHD pathophysiology may also influence brain volume 
variation. Recently, the first genome-wide significant loci for ADHD were identified, and a 
single-nucleotide polymorphism (SNP)-based heritability of 20.16% has been reported (8). 
In the present study, we investigated the genetic covariance between ADHD risk and 
structural brain phenotypes; we set out to determine whether common genetic variants are 
shared between ADHD risk and brain volumes that are found to be altered in ADHD (ICV 
and volumes of the nucleus accumbens, amygdala, caudate nucleus, hippocampus, and 
putamen). These volumes were selected to focus on the most robust imaging phenotypes in 
ADHD (3).
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Genome-wide association studies (GWASs) have identified 10 genome-wide significant loci 
associated with hippocampal volume (7, 9–12), eight with ICV (7, 9, 13, 14), four with 
putamen volume (7), and one with caudate volume (7). These variants explain only a small 
fraction of the heritability of these brain volumes (7, 9–11, 13). Recently, Franke and 
colleagues reported on a battery of statistical tools (15) to comprehensively examine genetic 
overlap between brain volumes and risk for brain disease at the genome-wide level and at 
the level of individual risk variants, using schizophrenia as an example. Here, we applied a 
similar set of methods to identify and dissect genetic sharing between ADHD and brain 
volumes implicated in ADHD based on the latest mega-analysis (3).
METHODS
This study used summary statistics of GWAS meta-analyses that were approved by local 
ethics committees and required informed consent (described in earlier publications [7, 8, 12, 
14]).
Participant Samples
We used summary statistics data from three consortia (see the Supplementary Methods 
section and Table S1 in the online supplement). GWAS meta-analysis data on ADHD were 
from the ADHD Working Group of the Psychiatric Genomics Consortium (PGC) and the 
ADHD iPSYCH-SSI-Broad collaboration (20,183 case subjects, 35,191 control subjects) 
(8).
GWAS meta-analysis summary statistics data on ICV and volumes of the nucleus 
accumbens, amygdala, caudate nucleus, hippocampus, and putamen (subcortical volumes 
were adjusted for ICV to identify specific genetic contributions to individual volumes) were 
from the Enhancing Neuroimaging Genetics Through Meta-Analysis (ENIGMA) 
consortium (7). For the initial GWAS meta-analysis data, MRI brain scans and genome-wide 
genotype data were available for 11,840 subjects. During the reviewing process, we added 
analyses on the other two subcortical volumes (pallidum and thalamus) for which large-scale 
genome-wide association data were available (7); results for those analyses can be found in 
the extended data sheet in the online supplement.
Lastly, we obtained summary statistics of additional GWAS meta-analysis data on ICV 
(N=12,803 [14]) and hippocampal volume (N=13,039 [12]) from the Cohorts for Heart and 
Aging Research in Genomic Epidemiology (CHARGE) Consortium. We did not have access 
to the original or preprocessed MRI scans, but rather used already existing summary 
statistics data based on initial GWAS meta-analyses that were performed for the different 
brain volumes of interest.
Before analyses were conducted, cohorts that included ADHD case subjects (N=154) were 
removed from the ENIGMA data (see the Supplementary Methods section in the online 
supplement). The summary statistics data from CHARGE were meta-analyzed with the 
ENIGMA data sets (see the Supplementary Methods section).
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To shed some light on the potential role of IQ in the relation between ADHD and brain 
volume genetics, we also used summary statistics from a GWAS meta-analysis on 
intelligence performed in 269,867 participants (16).
Linkage Disequilibrium Score Regression (LDSR)
GWAS meta-analysis data sets underwent additional filtering (see the Supplementary 
Methods section). The ADHD analysis included only results from studies with samples of 
European (Caucasian) genetic background (case subjects, N=19,099; control subjects, 
N=34,194). For the ENIGMA amygdala results, the mean chi-square was too low (1.0) to 
reliably estimate SNP heritability using LDSR. Table 1 lists genetic correlations between 
brain volumes.
The analysis used a two-step procedure with the linkage disequilibrium (LD) scoring 
analysis package (17). An unconstrained regression estimated regression intercepts for each 
phenotype. Since we took measures to exclude sample overlap, we also performed the 
analysis with the regression intercept defined as zero (see Table S2 in the online 
supplement). To compute p values, standard errors were estimated using a block jackknife 
procedure.
SNP Effect Concordance Analysis
Postprocessing of genetic data.—To statistically compare ADHD and six brain 
volume GWAS meta-analyses, we used SNPs that passed quality control and filtering rules 
in all data sets (see the Supplementary Methods section). The clumping procedure in PLINK 
(18) identified an independent SNP from every LD block across the genome, providing 
independent SNP sets representing the total variation explained across the genome 
conditioned on the significance in each brain volume GWAS meta-analysis (see the 
Supplementary Methods section). For each of these SNP sets, we determined the 
corresponding ADHD GWAS meta-analysis test statistic for each independent index SNP 
and used these data sets for subsequent analyses.
Tests of pleiotropy and concordance.—We used SNP effect concordance analysis 
(SECA) (19) to determine the extent and directionality of genetic overlap between ADHD 
and each brain volume. Within SECA, we performed a global test of pleiotropy using a 
binomial test at 12 p value levels (see the Supplementary Methods section). Similarly, a two-
sided Fisher’s exact test estimated concordance, the agreement in SNP effect directions 
across two traits. We determined whether there was a significant (p≤0.05) positive or 
negative trend in the effect of the overlapping SNPs at each p value threshold (see the 
Supplementary Methods section). In total, we tested for pleiotropy and concordance between 
ADHD and six brain volumes. The Bonferroni-corrected significance level was set at a p 
value of 4.17×10−3 (0.05/[2×6]).
SNP Sign Test in the Top GWAS Meta-Analysis Findings
To investigate a potential accumulation of same- or opposite-direction effects of SNPs 
between ADHD and brain volumes, we counted the number of opposite-direction effects (as 
expected from the imaging results in reference 3) for top findings from the ADHD data set 
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in the different brain structure data sets. The ADHD GWAS meta-analysis data were 
clumped to define independent loci (see the Supplementary Methods section) for all variants 
with p<1×10−5 in the ADHD GWAS meta-analysis using 1KGP3v5 (20) data on European-
ancestry populations as reference.
The proportion of variants with a discordant direction of effect in the individual brain GWAS 
meta-analyses was evaluated using a binomial test against a null hypothesis of 0.5 (i.e., 
chance level). This test was done for loci passing p value thresholds of 5×10−8 (14 LD-
independent genome-wide significant SNPs), 1×10−6 (44 LD-independent SNPs), and 
1×10−5 (132 LD-independent SNPs) in the ADHD GWAS meta-analysis. Details on the sign 
tests in the intelligence GWAS meta-analysis data (16) are provided in the Supplementary 
Methods section.
Weighted Meta-Analysis of ADHD and Brain Volume Data Sets
Independent of the results of the global overlap analyses, we also performed meta-analyses 
combining results from the ADHD GWAS meta-analysis with results from brain volume 
GWAS meta-analyses. We used a modified sample size–based weighting method, integrating 
the binary ADHD trait (ADHD risk) with the continuous trait (brain volume traits), as 
described in reference 8. The modified sample size–based weights were derived to account 
for the respective heritabilities, genetic correlation, and measurement scale of the GWAS 
meta-analyses (8; see also the Supplementary Methods section). For all brain volumes, we 
additionally performed naive meta-analyses given their low genetic correlations with ADHD 
risk. We set the threshold for genome-wide significance at a p value of 8.33×10−9 
(5×10−8/6).
Gene-Based and Gene-Set Analyses for ADHD and Brain GWAS Meta-Analysis Data
Genome-wide summary statistics of ADHD, individual brain, and weighted combined 
ADHD and brain-volume GWAS meta-analysis data sets were used as input for gene-based 
analyses, using the Multimarker Analysis of GenoMic Annotation (MAGMA) software 
package, version 1.05 (21; see also the Supplementary Methods section). For the combined 
ADHD and brain-volume GWAS meta-analysis, only SNPs shared between ADHD and 
brain volume data sets were included. Overlapping significant genes (p<2.731×10−6) were 
determined and selected for further investigation (see the Supplementary Methods section).
For gene-set analyses, we used self-contained and competitive testing and tested whether 
genes in the neurite-outgrowth gene set (defined previously, N=45 genes; see the 
Supplementary Methods section and reference 22) were jointly associated with results of the 
weighted meta-analytic data of ADHD and ICV (see the Supplementary Methods section). 
Post hoc, individual genes in the set were investigated by reviewing gene test statistics of the 
weighted combined ADHD and ICV GWAS meta-analysis results. Genes reaching 
Bonferroni correction threshold (p=0.05/45=0.00111) were considered gene-wide 
significant. Subsequently, we reviewed gene-based associations in the ADHD GWAS meta-
analysis and the ENIGMA and CHARGE ICV GWAS meta-analysis results separately.
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Reciprocal Lookup of Significant GWAS Meta-Analysis Loci
Evidence for an effect of ADHD-associated SNPs on brain volume was studied through a 
lookup of results in the ENIGMA GWAS meta-analyses (for ICV and hippocampus volume, 
the ENIGMA and CHARGE GWAS meta-analysis results were used). LD-independent loci 
with corresponding index SNPs were obtained by clumping the summary statistics of the 
ADHD GWAS meta-analysis (8) (see the Supplementary Methods section). Similarly, 
effects of 21 independent SNPs significantly associated with brain volumes in the original 
publications of the brain volume GWAS meta-analyses (7, 12, 14) on ADHD risk were 
looked up in the ADHD GWAS meta-analysis data. If the index variant was not present in 
the other data set, a proxy variant was selected through LDlink (https://
analysistools.nci.nih.gov/LDlink/). The Bonferroni-corrected significance levels were set at 
a p value of 0.000446 (0.05/[14×8]) for lookup of ADHD SNPs in brain volume GWAS 
meta-analysis data and at 0.002381 (0.05/21) for brain volume SNPs in ADHD GWAS 
meta-analysis data.
Expression Quantitative Trait Loci and Brain Gene Expression
Expression quantitative trait loci (eQTL) were examined using data from the GTEx portal 
(https://www.gtexportal.org/home/) (23) and the Blood eQTL Browser (http://
genenetwork.nl/bloodeqtlbrowser/) (24).
We investigated the spatiotemporal expression pattern in brain tissue for selected genes 
using data from the Human Brain Transcriptome Project (http://hbatlas.org). We assessed 
mRNA expression trajectories in six regions of the developing brain and the adult brain (see 
the Supplementary Methods section). Gene expression over the lifespan from the 
spatiotemporal atlas was graphed using custom R scripts (25).
RESULTS
Comparison of Common Variant Genetic Architectures
Linkage disequilibrium score regression.—SNP-based heritability estimates for the 
MRI measures were consistent with previous reports (12, 14, 15) and ranged from 13.32% to 
28.15% (Table 2). The amygdala mean chi-square was too small to allow a valid analysis. 
We observed a significant negative genetic correlation between ADHD and ICV (rg=−0.227, 
p=0.00015). All other correlations were nonsignificant (Table 2; Table S2 in the online 
supplement shows results when using constrained intercepts).
SNP effect concordance analysis.—SECA found significant evidence of global 
pleiotropy for variants affecting ADHD risk for volumes of four subcortical brain regions 
and ICV (Table 3; see also Figure S1 in the online supplement). Discordant SNP effects for 
ADHD and ICV were significant, that is, variants increasing the risk for ADHD were 
associated with decreased ICV (p<0.001) (Table 3; see also Figure S2 in the online 
supplement). Evidence for concordant SNP effects reached significance for ADHD and 
nucleus accumbens volume (p=0.002) and for ADHD and caudate nucleus volume 
(p=0.004) (Table 3; see also Figure S2).
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Sign tests.—Based on the phenotypic observation that patients with ADHD have, on 
average, smaller brain volumes compared with healthy control subjects (3), we had expected 
discordant rather than concordant SNP effects. As both discordant and concordant effects 
were seen in the SECA, we specifically determined directionality of genetic overlap between 
ADHD and brain volume for the top associations per trait. Thus, we zoomed in further on 
the most strongly associated and LD-independent SNPs and compared the signs of the 
regression coefficients of those top associations per trait. None of the sign tests showed a 
consistent direction of discordance after correction for multiple testing (see Table S3 in the 
online supplement). Additionally, LD-independent meta-analyzed ADHD and ICV-
associated SNPs showed an overrepresentation of discordant effects in GWAS meta-analysis 
data for intelligence (30 of 43 SNPs, proportion=0.698, p=0.0069) (see Table S4 in the 
online supplement) (16).
Analyses at the Single Genetic Variant Level
Weighted SNP meta-analyses.—Based on the findings of both concordant and 
discordant links between ADHD and the brain volume SNPs, we performed a genome-wide 
search for specific genetic loci associated with both ADHD and each brain trait. We used a 
weighted SNP meta-analysis design allowing the combination of findings from GWAS of 
binary and quantitative variables (8), enabling us to specifically look for concordant effects 
at the level of single genetic variants; there is currently no suitable method to study 
discordant effects. The weighted GWAS meta-analysis for ADHD and ICV identified two 
significant loci of interest: chromosome 15 (SEMA6D) and chromosome 16 (intergenic) 
(Table 4, Figures 1 and 2). Four additional loci passed the study-wide threshold for genome-
wide significance, but they were related to a single phenotype and did not meet criteria for 
cross-trait relevance (Figure 1).
We also performed weighted GWAS meta-analyses for ADHD and the four subcortical brain 
structures (see Figures S3–S7 in the online supplement). For amygdala volume, a naive 
sample size–weighted meta-analysis was performed, as no genetic correlation with ADHD 
had been estimated; the six novel and/or improved LD-independent genome-wide significant 
loci observed in these analyses are summarized in Table 4. Among those, the SEMA6D 
locus was significantly associated with ADHD and putamen volume (p=3.62×10−9) (see 
Table 4 and Figure 2; see also Figure S7 in the online supplement).
Gene-wide GWAS meta-analyses.—To maximize the power of the meta-analysis, we 
ran genome-wide gene-based GWAS meta-analyses in MAGMA; for gene-based results of 
all genes, see Tables S5–S10 in the online supplement. For the combined meta-analysis data 
of ADHD and ICV, three genome-wide significant genes (MEF2C, KIZ, and SEMA6D) 
showed stronger association in the cross-trait meta-analysis compared with the separate 
analyses of ADHD and ICV (see Table S11 in the online supplement). Additionally, the 
genome-wide significant genes FEZF1 (amygdala), ADD1 (caudate nucleus), and MANBA 
(hippocampus) showed increased significance in the cross-trait meta-analyses compared 
with the individual analyses of ADHD and brain volumes (see Tables S12–S16 in the online 
supplement).
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Reciprocal lookup of genome-wide significant associations.—No significant 
associations were observed between the 14 previously identified genome-wide significant 
ADHD SNPs (8) and brain volumes (see Table S17 in the online supplement). Conversely, 
among 21 SNPs previously associated with the brain volumes (7, 12, 14), association of two 
ICV-linked variants (rs8756 and rs2195243) with ADHD survived correction for multiple 
testing (p<0.00238) (see Table S18 in the online supplement).
Expression Quantitative Loci and Brain Gene Expression
Previously, it was shown that many SNPs in the SEMA6D locus were strongly associated 
with expression of SEMA6D in fibroblasts (8, 23). Indeed, repeating this analysis for the 
most strongly associated variants identified by the (weighted) cross-phenotype SNP meta-
analyses and the two significant variants of the reciprocal lookup using the GTEx data (23), 
we found rs281320 to be a significant eQTL for SEMA6D in transformed fibroblast tissue 
(p=1.2×10−20) (see Table S19 in the online supplement), as was rs281323 (p=1.2×10−21). 
The alternative alleles of both rs281320 and rs281323, which are associated with increased 
risk for ADHD and larger ICV, also increased SEMA6D expression (see Figure S9A, B in 
the online supplement). Additionally, rs12653396 was a significant eQTL for the 
CTC-498M16.4 and MEF2C genes in brain (p=2×10−7) (23) and blood tissue (p=6.53×10−7) 
(24), respectively, with the disease-associated A allele being associated with increased 
MEF2C expression (see Table S19 in the online supplement). Both rs8756 and rs2195243 
were eQTLs of HMGA2 and CCDC53, respectively. All other top SNPs were not present in 
either of the two eQTL databases.
We determined mRNA expression for SEMA6D and MEF2C, the only protein-coding genes 
identified in the SNP-based cross-phenotype GWAS meta-analyses and four significant 
genes (FEZF1, ADD1, MANBA, KIZ) identified in the gene-based cross-trait analyses, in 
six brain regions of the developing and adult brain using data from the Human Brain 
Transcriptome Project (25). All genes are globally expressed in the developing and adult 
brain, with SEMA6D and MEF2C showing highest mRNA expression in prenatal periods 
(see Figure S8 in the online supplement).
Neurite Outgrowth Gene-Set Analysis
In an exploratory analysis, we found an association between a predefined gene set of 45 
neurite outgrowth genes (22) and the meta-analytic data for the combined ADHD and ICV 
results using MAGMA (p=0.00338). It is current practice to use competitive tests, although 
for completeness we also report results from the self-contained analysis, which had a p value 
of 1.55×10−6. Associations of this set with ADHD, separately, were restricted to the self-
contained test (p=5.53×10−9); for ICV, no significant associations with the gene set were 
found (see Table S20 in the online supplement). In the cross-trait ADHD and ICV GWAS 
meta-analysis, the most strongly associated individual neurite outgrowth gene in the set was 
CREB5 (p=0.000553); nine additional neurite outgrowth genes showed nominally 
significant associations (see Table S21 in the online supplement; for gene-based results of all 
genes, see Table S10).
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In this study, we set out to investigate genetic covariance between ADHD risk and structural 
brain phenotypes. We found significant, though modest, genetic covariation between ADHD 
risk and brain volumes, both on global and gene-wide/single variant levels. On the global 
level, significant negative genetic correlation between ADHD and ICV was demonstrated. 
The direction of effect was supported by SNP effect concordance analysis. Our ICV finding 
was highly consistent across approaches and in the expected direction, given the previous 
observation that patients with ADHD have smaller ICV relative to control subjects (3). For 
most subcortical brain volumes, pleiotropic effects were also found. On the single variant 
and gene-wide levels, meta-analyses found significant loci associated with both ADHD risk 
and brain volumes. We identified SEMA6D, KIZ, and MEF2C as potential key loci 
contributing to both ADHD risk and ICV, and exploratory gene-set analysis revealed 
association of ADHD–ICV overlap with variation in neurite outgrowth genes.
A reduction of subcortical brain volumes and ICV is not unique to an ADHD diagnosis, but 
is also seen in depression and bipolar disorder (26, 27). However, genetic correlation 
between ADHD and ICV shows some specificity to this disorder, as it was not found in 
studies of other mental disorders, including schizophrenia (14, 15), major depressive 
disorder (28), and autism (14), using similar methods. On the other hand, power issues 
should not yet be discarded as a reason for the lack of finding genetic correlations, despite 
the large sample sizes, and results of a recent study found that schizophrenia and brain 
structure volumes share genetic risk factors using a conditional false discovery rate analysis 
(29). We also observed significant pleiotropy between ADHD and amygdala, caudate 
nucleus, hippocampus, and putamen volumes. This global genetic covariation was 
substantiated by local effects, which we observed in the weighted cross-phenotype meta-
analyses. In addition to ICV, variation in the volumes of the caudate nucleus and putamen 
also showed significant genetic concordance with ADHD. However, whereas results for ICV 
were in line with our expectation, concordant effects for ADHD and nucleus accumbens and 
caudate nucleus volume were counterintuitive (ADHD patients have smaller volumes for 
these structures [3]), suggesting a reverse or more complex pattern of causation. It should be 
noted that the subcortical regions were corrected for ICV phenotypically, so that their 
genetic correlation was limited.
On the single variant level, we only had tools available to perform a meta-analysis by 
looking at concordant effects (8), and we therefore had to ignore locus-specific discordant 
effects. Still, the strongest association of single genetic markers was observed for ADHD 
and ICV, and additional associations were identified for ADHD and subcortical volumes. 
The weighted meta-analysis of ADHD and ICV found two potentially pleiotropic loci. One 
of those was SEMA6D, coding for the semaphorin 6D, a transmembrane molecule important 
for maintenance and remodeling of neuronal connections (30). Animal studies have shown 
that it acts as ligand for PlexinA1, which is involved in neuronal development in the spinal 
cord (31). Together with the gene-based cross-trait result identifying the MEF2C gene and 
the findings in the exploratory gene-set analysis, our findings suggest that neurite outgrowth 
dysregulation may act as a neural mediator of ADHD. Dysregulation of neurite outgrowth 
may pose a more general genetic risk for psychopathology, as it has been shown to be 
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involved not only in ADHD (22, 32) and the hyperactive/impulsive symptom domain of 
ADHD (33) but also in dyslexia (34) and autism (35). We also found the SEMA6D locus in 
the cross-phenotype meta-analysis for ADHD and putamen volume, even though this 
volume had been corrected for ICV, suggesting that genetic variation in SEMA6D may 
influence specific brain regions to varying extents. In line with our gene-set association 
results, a recent study using data from the UK Biobank mainly found associations between 
MRI measures and genes involved in brain development and plasticity (36). Since most of 
these genes have also been demonstrated to contribute to different psychiatric and 
neurodegenerative disorders (36), specificity of our findings for ADHD requires additional 
investigation.
Our results in this study raise a number of questions concerning the way alterations in the 
brain mediate etiological risk pathways in ADHD. The first question is about the role of 
cognitive performance in this relationship. ADHD and ICV were recently shown to be 
genetically correlated with intelligence (ADHD is negatively genetically correlated with IQ 
[rg=−0.37, p=2.21×10−2], and ICV is positively correlated with IQ [37] [rg=0.29, 
p=3.44×10−4]). Similarly, educational attainment is linked to both ICV (rg=0.34, 
p=1.2×10−6) and ADHD (rg=−0.54, p=1.44×10−80), as well as to IQ (8, 38). It may therefore 
be possible that the genetic link between ADHD and ICV is mediated by IQ and its proxies. 
We attempted to test this—in the absence of IQ and educational attainment data to correct 
for in the ADHD GWAS meta-analysis—using a sign test based on data from the recent 
large intelligence GWAS meta-analysis (16). Here, we found an overrepresentation of 
opposite-direction effects of ADHD–ICV SNPs in the intelligence GWAS meta-analysis 
data, suggesting that intelligence may indeed play a role in the ADHD–ICV overlap. 
However, of the 43 SNPs included in the analysis, only 15 (34.8%) were nominally 
significantly associated with intelligence, suggesting that the genetic link between ADHD 
and ICV is additionally driven by intelligence-independent effects. More in-depth research 
will be needed to fully understand the role of intelligence in the ADHD–ICV overlap in the 
future; it may occur upstream and/or downstream of our correlation finding. Second, the 
degree of sharing observed was statistically modest. At first sight, this seems to be 
inconsistent with the general hypothesis that ADHD is a genetic-based braind is order. 
However, there are a number of possible explanations for this modest sharing. We examined 
brain structure at a gross anatomical scale; compared with more precise methods, such as 
voxel-based or surface-based morphometry, atlas-based brain segmentations may be too 
coarse to identify subtler volumetric differences. Notably, for the type of imaging genetics 
analyses described here, we were strongly dependent on the availability of GWAS data for 
brain phenotypes. These GWAS data have to be derived from large-scale studies to allow 
sufficiently powered analyses. Such data are, so far, available only for subcortical volumes 
and ICV, published by the ENIGMA and CHARGE consortia. The sample sizes of the few 
voxel-wise GWASs available to date are not large enough to offer sufficient statistical power 
for the genome-wide approaches presented here. Moreover, it may be more informative to 
study structural and functional connectivity measures. In addition, as pointed out previously 
(15), the limited SNP heritability of subcortical brain volumes further challenges the 
identification of genetic overlap, and more highly powered studies of brain phenotypes may 
lead to higher estimates of overlap. Also, the field may advance by applying more 
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sophisticated imaging approaches to imaging genetics studies, such as redefining imaging 
phenotypes through dimension reduction approaches (39). Finally, it is also possible that 
some of ADHD’s association with reduced brain volumes is driven by environmental effects, 
either independently or in interaction with genetic factors (1).
Previous brain imaging genetics studies in ADHD have mainly focused on single genetic 
variants and have been hampered by limited sample sizes (40). This study combined the 
largest data sets available to investigate the genetic overlap between ADHD and brain 
volumes by using a complementary battery of statistical methods. Nevertheless, some 
limitations apply. First, this study focused on a limited set of mainly subcortical MRI 
measures, and future work should be extended to cortical regions and connectivity measures, 
once large-scale GWAS meta-analysis becomes available (4, 41). To support highly 
sophisticated imaging genetics analyses, which can provide granular information on specific 
circuits of relevance, there is also an increasing need for large-scale imaging cohorts with 
raw imaging and genetic data that allow maximal flexibility in the application of analytic 
methods. Second, for the cross-phenotype GWAS meta-analysis, we used a recently 
described weighted meta-analysis method (8). However, we observed that with low and 
moderate genetically correlated phenotypes, the association signals generally did not 
improve over a naive meta-analysis performed without adding additional weights (see Figure 
S10 and Table S22 in the online supplement). In addition, we could only investigate 
concordant SNP effects with this method. Third, generalization of our findings to other 
ethnicities should be assessed in future studies. Fourth, it is possible that this study 
underestimated genetic correlations, as we did not take into account the known role of rare 
and structural variants in the genetic architecture of ADHD (42, 43). Future studies 
investigating heritability and genetic correlation could also benefit from including variants 
with low minor allele frequency and in low-LD regions, which may reveal stronger 
relationships between ADHD and brain volumes.
To our knowledge, this is the first study to show significant global and single gene/variant 
level genetic correlations derived from polygenic overlap between ADHD and brain 
volumes. The modest genetic overlap between ADHD and variation in brain volumes is 
consistent with models implicating alterations in brain structure in ADHD-related genetic 
risk pathways and provides new hypotheses about neurobiological mechanisms involved in 
ADHD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1. Common genetic variants associated with ADHD, intracranial volume (ICV), and 
the combined analysis of ADHD and ICVa
A. ADHD GWAS Meta-Analysis (PGC and iPSYCH Data)
B. ICV GWAS Meta-Analysis (ENIGMA and CHARGE Data)
C. Combined ADHD and ICV Weighted GWAS Meta-Analysis
aShown here are Manhattan plots, in which every point represents a single genetic variant 
plotted according to its genomics position (x-axis) and its −log10(p) value for association 
with the respective trait (y-axis). The solid red line represents the study-wide genome-wide 
significance of p<8.33×10−9, and the dashed red line represents the genome-wide 
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significance of p<5×10−8. ADHD=attention deficit hyperactivity disorder; 
CHARGE=Cohorts for Heart and Aging Research in Genomic Epidemiology; 
ENIGMA=Enhancing Neuroimaging Genetics Through Meta-Analysis; GWAS=genome-
wide association study; PGC=Psychiatric Genomics Consortium.
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FIGURE 2. Regional association of genome-wide significant loci of ADHD and brain volume 
GWAS meta-analysesa
a For each panel, zoomed-in association plots (±300 kb from the top SNP, indexed by purple 
diamond) are shown. Plots are zoomed to highlight the genomic region that likely harbors 
the causal variant(s). ADHD=attention deficit hyperactivity disorder; nMA=naive meta-
analysis of ADHD and brain volume; wMA=weighted meta-analysis of ADHD and brain 
volume; SNP=single-nucleotide polymorphism.
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